| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Isolation and characterization of multipotent progenitor cells from the Bowman's capsule of adult human kidneys.
|
J Am Soc Nephrol
|
2006
|
3.95
|
|
2
|
Regeneration of glomerular podocytes by human renal progenitors.
|
J Am Soc Nephrol
|
2008
|
3.80
|
|
3
|
An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4.
|
J Exp Med
|
2003
|
2.91
|
|
4
|
Regenerative potential of embryonic renal multipotent progenitors in acute renal failure.
|
J Am Soc Nephrol
|
2007
|
2.42
|
|
5
|
Essential but differential role for CXCR4 and CXCR7 in the therapeutic homing of human renal progenitor cells.
|
J Exp Med
|
2008
|
2.25
|
|
6
|
Metalloproteinases-2, -9 and TIMP-1 expression in stable and unstable coronary plaques undergoing PCI.
|
Int J Cardiol
|
2007
|
2.05
|
|
7
|
CXC chemokines: the regulatory link between inflammation and angiogenesis.
|
Trends Immunol
|
2004
|
1.77
|
|
8
|
Seladin-1 is a fundamental mediator of the neuroprotective effects of estrogen in human neuroblast long-term cell cultures.
|
Endocrinology
|
2008
|
1.46
|
|
9
|
Role of chemokines in endocrine autoimmune diseases.
|
Endocr Rev
|
2007
|
1.43
|
|
10
|
CXCR3-mediated opposite effects of CXCL10 and CXCL4 on TH1 or TH2 cytokine production.
|
J Allergy Clin Immunol
|
2005
|
1.35
|
|
11
|
Functional differences in visceral and subcutaneous fat pads originate from differences in the adipose stem cell.
|
PLoS One
|
2012
|
1.25
|
|
12
|
Characterization of human adult stem-cell populations isolated from visceral and subcutaneous adipose tissue.
|
FASEB J
|
2009
|
1.13
|
|
13
|
High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism.
|
J Clin Endocrinol Metab
|
2004
|
1.11
|
|
14
|
Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists.
|
J Clin Endocrinol Metab
|
2005
|
1.07
|
|
15
|
Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased levels of IP-10/CXCL10 in the serum of patients with recent-onset Graves' disease.
|
Am J Pathol
|
2002
|
1.06
|
|
16
|
High CXCL10 expression in rejected kidneys and predictive role of pretransplant serum CXCL10 for acute rejection and chronic allograft nephropathy.
|
Transplantation
|
2005
|
1.02
|
|
17
|
Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.
|
Clin Endocrinol (Oxf)
|
2006
|
0.99
|
|
18
|
IP-10 and Mig production by glomerular cells in human proliferative glomerulonephritis and regulation by nitric oxide.
|
J Am Soc Nephrol
|
2002
|
0.98
|
|
19
|
The CXCR4/CXCL12 axis in endometrial cancer.
|
Clin Exp Metastasis
|
2009
|
0.97
|
|
20
|
Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R.
|
J Clin Endocrinol Metab
|
2004
|
0.97
|
|
21
|
Increase of CXC chemokine CXCL10 and CC chemokine CCL2 serum levels in normal ageing.
|
Cytokine
|
2006
|
0.96
|
|
22
|
Peroxisome proliferator-activated receptor gamma (PPARgamma): Is the genomic activity the only answer?
|
Steroids
|
2009
|
0.96
|
|
23
|
High pretransplant serum levels of CXCL10/IP-10 are related to increased risk of renal allograft failure.
|
Am J Transplant
|
2004
|
0.95
|
|
24
|
Rosiglitazone inhibits adrenocortical cancer cell proliferation by interfering with the IGF-IR intracellular signaling.
|
PPAR Res
|
2008
|
0.95
|
|
25
|
Androgen receptor regulation of the seladin-1/DHCR24 gene: altered expression in prostate cancer.
|
Lab Invest
|
2008
|
0.94
|
|
26
|
PF-4/CXCL4 and CXCL4L1 exhibit distinct subcellular localization and a differentially regulated mechanism of secretion.
|
Blood
|
2007
|
0.94
|
|
27
|
Inflammatory response in human skeletal muscle cells: CXCL10 as a potential therapeutic target.
|
Eur J Cell Biol
|
2011
|
0.94
|
|
28
|
Estrogen and selective estrogen receptor modulators exert neuroprotective effects and stimulate the expression of selective Alzheimer's disease indicator-1, a recently discovered antiapoptotic gene, in human neuroblast long-term cell cultures.
|
J Clin Endocrinol Metab
|
2004
|
0.93
|
|
29
|
A new mechanism involving ERK contributes to rosiglitazone inhibition of tumor necrosis factor-alpha and interferon-gamma inflammatory effects in human endothelial cells.
|
Arterioscler Thromb Vasc Biol
|
2008
|
0.93
|
|
30
|
Expression of the antiapoptotic gene seladin-1 and octreotide-induced apoptosis in growth hormone-secreting and nonfunctioning pituitary adenomas.
|
J Clin Endocrinol Metab
|
2005
|
0.93
|
|
31
|
Neuronal differentiation of human mesenchymal stem cells: changes in the expression of the Alzheimer's disease-related gene seladin-1.
|
Exp Cell Res
|
2006
|
0.92
|
|
32
|
Up-regulated expression of low molecular weight protein tyrosine phosphatases in different human cancers.
|
Biochem Biophys Res Commun
|
2005
|
0.90
|
|
33
|
Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process.
|
Eur J Endocrinol
|
2006
|
0.90
|
|
34
|
Quantitative evaluation of somatostatin receptor subtype 2 expression in sporadic colorectal tumor and in the corresponding normal mucosa.
|
Clin Cancer Res
|
2002
|
0.89
|
|
35
|
Elevated serum interferon-gamma-inducible chemokine-10/CXC chemokine ligand-10 in autoimmune primary adrenal insufficiency and in vitro expression in human adrenal cells primary cultures after stimulation with proinflammatory cytokines.
|
J Clin Endocrinol Metab
|
2005
|
0.89
|
|
36
|
Expression of the novel adrenocorticotropin-responsive gene selective Alzheimer's disease indicator-1 in the normal adrenal cortex and in adrenocortical adenomas and carcinomas.
|
J Clin Endocrinol Metab
|
2004
|
0.89
|
|
37
|
High pretransplant serum levels of CXCL9 are associated with increased risk of acute rejection and graft failure in kidney graft recipients.
|
Transpl Int
|
2009
|
0.88
|
|
38
|
Simultaneous measurement of MMP9 and TIMP1 mRNA in human non small cell lung cancers by multiplex real time RT-PCR.
|
Lung Cancer
|
2004
|
0.88
|
|
39
|
Predictive role of pretransplant serum CXCL10 for cardiac acute rejection.
|
Transplantation
|
2009
|
0.88
|
|
40
|
Molecular mechanisms underlying the pro-inflammatory synergistic effect of tumor necrosis factor alpha and interferon gamma in human microvascular endothelium.
|
Eur J Cell Biol
|
2009
|
0.88
|
|
41
|
Neuroprotective effects of the Alzheimer's disease-related gene seladin-1.
|
J Mol Endocrinol
|
2008
|
0.88
|
|
42
|
Rosiglitazone impairs proliferation of human adrenocortical cancer: preclinical study in a xenograft mouse model.
|
Endocr Relat Cancer
|
2010
|
0.87
|
|
43
|
Serum CXCL10 levels and occurrence of thyroid dysfunction in patients treated with interferon-alpha therapy for hepatitis C virus-related hepatitis.
|
Eur J Endocrinol
|
2007
|
0.87
|
|
44
|
A case of hyponatremia caused by central hypocortisolism.
|
Nat Clin Pract Endocrinol Metab
|
2007
|
0.86
|
|
45
|
Vitamin D3 analogue inhibits keratinocyte growth factor signaling and induces apoptosis in human prostate cancer cells.
|
Prostate
|
2002
|
0.86
|
|
46
|
New insights on the neuroprotective role of sterols and sex steroids: the seladin-1/DHCR24 paradigm.
|
Front Neuroendocrinol
|
2009
|
0.85
|
|
47
|
Globular adiponectin induces differentiation and fusion of skeletal muscle cells.
|
Cell Res
|
2009
|
0.85
|
|
48
|
Gonadotropin-releasing hormone modulates cholesterol synthesis and steroidogenesis in SH-SY5Y cells.
|
J Steroid Biochem Mol Biol
|
2011
|
0.84
|
|
49
|
Low serum and peritoneal fluid concentration of interferon-gamma-induced protein-10 (CXCL10) in women with endometriosis.
|
Fertil Steril
|
2008
|
0.83
|
|
50
|
Interferon-alpha, -beta and -gamma induce CXCL9 and CXCL10 secretion by human thyrocytes: modulation by peroxisome proliferator-activated receptor-gamma agonists.
|
Cytokine
|
2010
|
0.83
|
|
51
|
Correlation between, clinical, biochemical, color Doppler ultrasound thyroid parameters, and CXCL-10 in autoimmune thyroid diseases.
|
Endocr J
|
2008
|
0.83
|
|
52
|
Pretransplant serum FT3 levels in kidney graft recipients are useful for identifying patients with higher risk for graft failure.
|
Clin Endocrinol (Oxf)
|
2007
|
0.81
|
|
53
|
Synthesis, biological activity, and three-dimensional quantitative structure-activity relationship model for a series of benzo[c]quinolizin-3-ones, nonsteroidal inhibitors of human steroid 5alpha-reductase 1.
|
J Med Chem
|
2004
|
0.81
|
|
54
|
Expression of cAMP response element-binding protein and sodium iodide symporter in benign non-functioning and malignant thyroid tumours.
|
Eur J Endocrinol
|
2003
|
0.81
|
|
55
|
Comparison between VDR analogs and current immunosuppressive drugs in relation to CXCL10 secretion by human renal tubular cells.
|
Transpl Int
|
2010
|
0.80
|
|
56
|
Seladin-1 and testicular germ cell tumours: new insights into cisplatin responsiveness.
|
J Pathol
|
2009
|
0.80
|
|
57
|
PPARgamma in Neuroblastoma.
|
PPAR Res
|
2008
|
0.80
|
|
58
|
Age-dependent changes in CXC chemokine ligand 10 serum levels in euthyroid subjects.
|
J Interferon Cytokine Res
|
2005
|
0.80
|
|
59
|
Real-time RT-PCR for the measurement of prostate-specific antigen mRNA expression in benign hyperplasia and adenocarcinoma of prostate.
|
Clin Chem Lab Med
|
2003
|
0.79
|
|
60
|
Increase of interferon-gamma inducible alpha chemokine CXCL10 but not beta chemokine CCL2 serum levels in chronic autoimmune thyroiditis.
|
Eur J Endocrinol
|
2005
|
0.79
|
|
61
|
Selective non-steroidal inhibitors of 5 alpha-reductase type 1.
|
J Steroid Biochem Mol Biol
|
2004
|
0.79
|
|
62
|
Immunosuppression in cardiac graft rejection: a human in vitro model to study the potential use of new immunomodulatory drugs.
|
Exp Cell Res
|
2008
|
0.79
|
|
63
|
Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter.
|
J Clin Endocrinol Metab
|
2007
|
0.78
|
|
64
|
Synthesis and activity of 8-substituted benzo[c]quinolizin-3-ones as dual inhibitors of human 5alpha-reductases 1 and 2.
|
Bioorg Med Chem Lett
|
2005
|
0.77
|
|
65
|
New evidence of similarity between human and plant steroid metabolism: 5alpha-reductase activity in Solanum malacoxylon.
|
Endocrinology
|
2003
|
0.77
|
|
66
|
Expression of uteroglobin and matrix metalloproteinase-9 genes in endometrial cancer: relationship to estrogen and progesterone receptor status.
|
Oncol Rep
|
2004
|
0.77
|
|
67
|
Peroxisome-proliferator-activated receptor gamma (PPARgamma) is required for modulating endothelial inflammatory response through a nongenomic mechanism.
|
Eur J Cell Biol
|
2010
|
0.76
|
|
68
|
Estrogen receptor-mediated neuroprotection: The role of the Alzheimer's disease-related gene seladin-1.
|
Neuropsychiatr Dis Treat
|
2008
|
0.76
|
|
69
|
Vitamin D therapy in adults with diabetes mellitus.
|
Nat Rev Endocrinol
|
2011
|
0.76
|
|
70
|
Cushing's syndrome in a patient with bilateral macronodular adrenal hyperplasia responding to cisapride: an in vivo and in vitro study.
|
J Clin Endocrinol Metab
|
2003
|
0.76
|
|
71
|
Identification of a novel mutation in the arginine vasopressin-neurophysin II gene affecting the sixth intrachain disulfide bridge of the neurophysin II moiety.
|
Eur J Endocrinol
|
2004
|
0.75
|
|
72
|
Pretransplant positivity for circulating thyroid antibodies and graft survival in patients undergoing kidney transplant.
|
Horm Res
|
2009
|
0.75
|
|
73
|
Prognostic value of somatostatin receptor subtype 2 expression in colorectal cancer.
|
Regul Pept
|
2005
|
0.75
|
|
74
|
Expression of cAMP-responsive element binding protein and inducible cAMP early repressor in hyperfunctioning thyroid adenomas.
|
Eur J Endocrinol
|
2002
|
0.75
|
|
75
|
5alpha-Reductase activity in Lycopersicon esculentum: cloning and functional characterization of LeDET2 and evidence of the presence of two isoenzymes.
|
J Steroid Biochem Mol Biol
|
2005
|
0.75
|
|
76
|
Synthesis of 17beta-N-substituted 19-Nor-10-azasteroids as inhibitors of human 5alpha-reductases I and II.
|
Bioorg Med Chem
|
2002
|
0.75
|